129 related articles for article (PubMed ID: 35218306)
1. Cutaneous Angiosarcomas: Molecular Pathogenesis Guides Novel Therapeutic Approaches.
Goerdt LV; Schneider SW; Booken N
J Dtsch Dermatol Ges; 2022 Apr; 20(4):429-443. PubMed ID: 35218306
[TBL] [Abstract][Full Text] [Related]
2. A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol).
Oashi K; Shibata T; Namikawa K; Takahashi A; Yokota K; Nakano E; Teramoto Y; Tsutsumida A; Maeda T; Yamazaki N;
BMC Cancer; 2020 Jul; 20(1):652. PubMed ID: 32660439
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous angiosarcoma: update on biology and latest treatment.
Ishida Y; Otsuka A; Kabashima K
Curr Opin Oncol; 2018 Mar; 30(2):107-112. PubMed ID: 29194075
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
5. Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma.
Boutros C; Rouleau E; Majer M; Nikolaev S; Robert C
Eur J Cancer; 2021 Jun; 150():130-132. PubMed ID: 33901791
[No Abstract] [Full Text] [Related]
6. Irradiation-induced angiosarcoma and anti-angiogenic therapy: a therapeutic hope?
Azzariti A; Porcelli L; Mangia A; Saponaro C; Quatrale AE; Popescu OS; Strippoli S; Simone G; Paradiso A; Guida M
Exp Cell Res; 2014 Feb; 321(2):240-7. PubMed ID: 24384475
[TBL] [Abstract][Full Text] [Related]
7. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
Wu B; Shi L
JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
[TBL] [Abstract][Full Text] [Related]
8. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).
Wagner MJ; Othus M; Patel SP; Ryan C; Sangal A; Powers B; Budd GT; Victor AI; Hsueh CT; Chugh R; Nair S; Leu KM; Agulnik M; Sharon E; Mayerson E; Plets M; Blanke C; Streicher H; Chae YK; Kurzrock R
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34380663
[TBL] [Abstract][Full Text] [Related]
9. Primary and secondary cutaneous angiosarcoma: Distinctive clinical, pathological and molecular features.
Ronchi A; Cozzolino I; Zito Marino F; De Chiara A; Argenziano G; Moscarella E; Pagliuca F; Franco R
Ann Diagn Pathol; 2020 Oct; 48():151597. PubMed ID: 32829071
[TBL] [Abstract][Full Text] [Related]
10. Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing.
Boichard A; Wagner MJ; Kurzrock R
Genome Med; 2020 Jul; 12(1):61. PubMed ID: 32646514
[TBL] [Abstract][Full Text] [Related]
11. Optimal Clinical Management and the Molecular Biology of Angiosarcomas.
Chen TW; Burns J; Jones RL; Huang PH
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33182685
[TBL] [Abstract][Full Text] [Related]
12. Multiomic analysis and immunoprofiling reveal distinct subtypes of human angiosarcoma.
Chan JY; Lim JQ; Yeong J; Ravi V; Guan P; Boot A; Tay TKY; Selvarajan S; Md Nasir ND; Loh JH; Ong CK; Huang D; Tan J; Li Z; Ng CC; Tan TT; Masuzawa M; Sung KW; Farid M; Quek RHH; Tan NC; Teo MCC; Rozen SG; Tan P; Futreal A; Teh BT; Soo KC
J Clin Invest; 2020 Nov; 130(11):5833-5846. PubMed ID: 33016928
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous Angiosarcoma: Clinical and Pathology Study of 16 Cases.
Requena C; Sendra E; Llombart B; Sanmartín O; Guillén C; Lavernia J; Traves V; Cruz J
Actas Dermosifiliogr; 2017 Jun; 108(5):457-465. PubMed ID: 28318524
[TBL] [Abstract][Full Text] [Related]
14. Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma.
Ogata D; Yanagisawa H; Suzuki K; Oashi K; Yamazaki N; Tsuchida T
Med Oncol; 2016 Oct; 33(10):116. PubMed ID: 27613162
[TBL] [Abstract][Full Text] [Related]
15. Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients.
Machado MAÁ; de Moura CS; Chan K; Curtis JR; Hudson M; Abrahamowicz M; Jamal R; Pilote L; Bernatsky S
Sci Rep; 2020 Sep; 10(1):14607. PubMed ID: 32884119
[TBL] [Abstract][Full Text] [Related]
16. Angiosarcoma of the scalp responding to nivolumab: a case report.
Hofer S; Zeidler K; Schipf A; Kempf W; Zimmermann D; Aebi S
Br J Dermatol; 2018 Aug; 179(2):530-531. PubMed ID: 29700818
[No Abstract] [Full Text] [Related]
17. Cutaneous angiosarcoma: a current update.
Shustef E; Kazlouskaya V; Prieto VG; Ivan D; Aung PP
J Clin Pathol; 2017 Nov; 70(11):917-925. PubMed ID: 28916596
[TBL] [Abstract][Full Text] [Related]
18. Current Management of Angiosarcoma: Recent Advances and Lessons From the Past.
Florou V; Wilky BA
Curr Treat Options Oncol; 2021 Jun; 22(7):61. PubMed ID: 34097172
[TBL] [Abstract][Full Text] [Related]
19. Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment.
Hoshina D; Abe R; Yoshioka N; Saito N; Hata H; Fujita Y; Aoyagi S; Shimizu H
J Dermatol Sci; 2013 May; 70(2):116-22. PubMed ID: 23522954
[TBL] [Abstract][Full Text] [Related]
20. Growth Attenuation of Cutaneous Angiosarcoma With Propranolol-Mediated β-Blockade.
Chow W; Amaya CN; Rains S; Chow M; Dickerson EB; Bryan BA
JAMA Dermatol; 2015 Nov; 151(11):1226-9. PubMed ID: 26375166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
